Lara Meisner - Dec 15, 2022 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
General Counsel and Secretary
Signature
/s/ Kristian Humer, Attorney-in-Fact for Lara Meisner
Stock symbol
VRDN
Transactions as of
Dec 15, 2022
Transactions value $
-$8,532
Form type
4
Date filed
12/19/2022, 06:22 PM
Previous filing
Dec 14, 2022
Next filing
Dec 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRDN Common Stock Options Exercise $6.91K +300 $23.03 300 Dec 15, 2022 Direct
transaction VRDN Common Stock Sale -$8.42K -300 -100% $28.08 0 Dec 15, 2022 Direct F1
transaction VRDN Common Stock Options Exercise $29.9K +1.3K $23.03 1.3K Dec 16, 2022 Direct
transaction VRDN Common Stock Sale -$36.9K -1.3K -100% $28.44 0 Dec 16, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -300 -0.47% $0.00 62.9K Dec 15, 2022 Common Stock 300 $23.03 Direct F3
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -1.3K -2.06% $0.00 61.6K Dec 16, 2022 Common Stock 1.3K $23.03 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.115. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.72. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.